Adult botulism type F in the United States, 1981-2002

Neurology

Volumn 65, Issue 11, 2005, Pages 1694-1700

  Gupta, A ^a,b,d   Sumner, C J ^c   Castor, M ^a   Maslanka, S ^b   Sobel, J ^b  

^a Epidemiology Program Office   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITOXIN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; BOTULINUM TOXIN F; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; CLOSTRIDIUM BARATI F TOXIN;

ADULT; ADULTHOOD; AGED; ARTIFICIAL VENTILATION; BACTERIUM IDENTIFICATION; BOTULISM; CLINICAL FEATURE; CLOSTRIDIUM; CLOSTRIDIUM BARATII; CLOSTRIDIUM BOTULINUM; DISEASE CLASSIFICATION; DISEASE COURSE; EARLY DIAGNOSIS; EPIDEMIC; FECES CULTURE; FEMALE; FOOD CONTAMINATION; HUMAN; LABORATORY TEST; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEUROMUSCULAR FUNCTION; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; QUADRIPLEGIA; RESPIRATORY FAILURE; REVIEW; TOXIN ANALYSIS; TREATMENT DURATION; UNITED STATES; ARTICLE; INCIDENCE; INFANT; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PHYSIOLOGY; RETROSPECTIVE STUDY; STATISTICS; TIME;

ADULT; BACTERIAL PROTEINS; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LENGTH OF STAY; MALE; MIDDLE AGED; QUADRIPLEGIA; RESPIRATION, ARTIFICIAL; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 33645066410     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000187127.92446.4c     Document Type: Review

References (33)

1. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998;129:221-228.
2. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059-1070.
3. Hatheway CL. Toxigenic clostridia. Clin Microbiol Rev 1990;3:66-98.
4. Middlebrook JL. Botulinum toxins. In: Sidell FR, ed. Medical aspects of chemical and biological warfare. Washington, DC: Borden Institute, Walter Reed Army Medical Center, 1997;643-654.
5. Hatheway CL, Ferreira JL. Detection and identification of Clostridium botulinum neurotoxins. Adv Exp Med Biol 1996;391:481-498.
6. Fenicia L, Franciosa G, Pourshaban M, Aureli P. Intestinal toxemia botulism in two young people, caused by Clostridium butyricum type E. Clin Infect Dis 1999;29:1381-1387.
7. Green J, Spear H, Brinson RR. Human botulism (type F) - a rare type. Am J Med 1983;75:893-895.
8. Harvey SM, Sturgeon J, Dassey DE. Botulism due to Clostridium baratii type F toxin. J Clin Microbiol 2002;40:2260-2262.
9. McCroskey LM, Hatheway CL, Woodruff BA, Greenberg JA, Jurgenson P. Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult. J Clin Microbiol 1991;29:2618-2620.
10. Moller V, Scheibel I. Preliminary report on the isolation of an apparently new type of Clostridium botulinum. Acta Pathol Microbiol Scand 1960;48:80.
11. CDC. Epidemiologic notes and reports - botulism type F - California. MMWR 1966;15:359.
12. Hall JD, McCroskey LM, Pincomb BJ, Hatheway CL. Isolation of an organism resembling Clostridium baratii which produces type F botulinal toxin from an infant with botulism. J Clin Microbiol 1985;21:654-655.
13. Hoffman RE, Pincomb BJ, Skeels MR. Type F infant botulism. Am J Dis Child 1982;136:270-271.
14. Richardson WH, Frei SS, Williams SR. A case of type F botulism in southern California. J Toxicol Clin Toxicol 2004;42:383-387.
15. CDC. Botulism in the United States, 1899-1996: handbook for epidemiologists, clinicians, and laboratory workers. 1998. Atlanta. Available at: http://www.cdc.gov/ncidod/dbmd/diseaseinfo/botulism.pdf
16. Hatheway C. Botulism. In: Balows A, Lennette EH, eds. Laboratory diagnosis of infectious diseases: principles and practice. New York: Springer-Verlag, 1998;111.
17. Cherington M. Electrophysiologic methods as an aid in diagnosis of botulism: a review. Muscle Nerve 1982;5:28-39.
18. Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VR, Gangarosa EJ. Clinical features of types A and B food-borne botulism. Ann Intern Med 1981;95:442-445.
19. Woodruff BA, Griffin PM, McCroskey LM, et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975-1988. J Infect Dis 1992;166:1281-1286.
20. Paisley JW, Lauer BA, Arnon SS. A second case of infant botulism type F caused by Clostridium baratii. Pediatr Infect Dis J 1995;14:912-914.
21. Keet CA, Fox CK, Margeta M, et al. Infant botulism, type F, presenting at 54 hours of life. Pediatr Neurol 2005;32:193-196.
22. Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 2003;22:454-466.
23. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999;96:3200-3205.
24. Billante CR, Zealear DL, Billante M, et al. Comparison of neuromuscular blockade and recovery with botulinum toxins A and F. Muscle Nerve 2002;26:395-403.
25. Foran PG, Davletov B, Meunier FA. Getting muscles moving again after botulinum toxin: novel therapeutic challenges. Trends Mol Med 2003;9:291-299.
26. Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004;44:167-193.
27. Foran PG, Mohammed N, Lisk GO, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 2003;278:1363-1371.
28. McCroskey LM, Hatheway CL. Laboratory findings in four cases of adult botulism suggest colonization of the intestinal tract. J Clin Microbiol 1988;26:1052-1054.
29. Chia JK, Clark JB, Ryan CA, Pollack M. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N Engl J Med 1986;315:239-241.
30. Eklund MW, Poysky FT, Wieler DI. Characteristics of Clostridium botulinum type F isolated from the Pacific Coast of the United States. Appl Microbiol 1967;15:1316-1323.
31. Smith LD. The occurrence of Clostridium botulinum and Clostridium tetani in the soil of the United States. Health Laboratory Science 1978;15:74-80.
32. Elmore MJ, Hutson RA, Collins MD, Bodsworth NJ, Whelan SM, Minton NP. Nucleotide sequence of the gene coding for proteolytic (Group I) Clostridium botulinum type F neurotoxin: genealogical comparison with other clostridial neurotoxins. System Appl Microbiol 1995;18:23-31.
33. Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984;76:794-798.